Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer
Breast Cancer
About this trial
This is an interventional treatment trial for Breast Cancer focused on measuring male breast cancer, stage I breast cancer, stage II breast cancer, stage IIIA breast cancer
Eligibility Criteria
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed invasive breast cancer meeting the following criteria:
Early-stage disease
- No stage IV disease
- More than one synchronous primary breast tumor
- Lymph node positive OR high-risk lymph node negative
Candidate for treatment with anthracycline- and taxane-based chemotherapy in the adjuvant setting
- Must begin therapy within 84 days after the final required surgical procedure
- HER2/neu-negative breast cancer, defined as an immunohistochemistry (IHC) score of 0, 1+ or 2+ and fluorescent in situ hybridization (FISH) not amplified
- No CNS disease (e.g., primary brain tumor or brain metastasis)
- Hormone receptor status known
PATIENT CHARACTERISTICS:
- Male or female
- Pre- or post-menopausal
- ECOG performance status 0-1
- Absolute neutrophil count ≥ 1,000/mm^3
- Platelet count ≥ 100,000/mm^3
- Bilirubin normal
- AST or ALT ≤ 2.5 times upper limit of normal
- Creatinine normal OR creatinine clearance ≥ 60 mL/min
- Urine protein:creatinine ratio ≤ 1.0
- PT and PTT normal
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 6 months after completion of study therapy
- LVEF normal by MUGA scan at baseline
- No significant bleeding within the past 6 months
- No uncontrolled underlying bleeding diathesis
No nonmalignant systemic disease (e.g., cardiovascular, renal, or hepatic) that would preclude study therapy, including any of the following conditions:
- Blood pressure > 150/100 mm Hg
- Unstable angina
- New York Heart Association class II -IV congestive heart failure
- Myocardial infarction or stroke within the past 12 months
- Clinically significant peripheral vascular disease
- No seizures not controlled with standard medical therapy
- No history of stroke
- No known allergy or hypersensitivity to study drugs (prior hypersensitivity to paclitaxel allowed)
- No significant traumatic injury within the past 28 days
- No serious nonhealing wound, ulcer, or bone fracture
- No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months
- No active gastroduodenal ulcer
- No uncontrolled intercurrent illness, including psychiatric illness or social situation that would limit compliance with study requirements
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Prior therapy for an ipsilateral or contralateral breast cancer primary allowed provided the following criteria are met:
- No prior anthracycline therapy
- Prior hormonal therapy for this previous breast cancer is allowed, but must be stopped during study therapy
- At least 1 year since prior taxane therapy
More than 28 days since prior and no concurrent major surgery or open biopsy
- Anticipated reconstructive surgery (e.g., tissue expander exchange) is allowed during the course of the study (bevacizumab will be held during that time as per protocol guidelines)
More than 7 days since prior minor surgery, including fine-needle aspiration or core biopsy
- At least 24 hours since prior indwelling catheter placement
- No prior bevacizumab or other KDR inhibitors (e.g., VEGF Trap, semaxanib, SU6668, vandetanib, vatalanib, AEE788, or IMC-1CII)
- No concurrent full-dose anticoagulation therapy
- No concurrent hormonal therapy as chemoprevention
- Concurrent participation in adjuvant hormone therapy or correlative or companion (e.g., bisphosphonate clinic) studies allowed
- No other concurrent anticancer therapy
Sites / Locations
- Memorial Sloan-Kettering Cancer Center